Novartis Study Shows Jakavi Reduces Blood Clots, Risk of Death
June 15 2018 - 3:35AM
Dow Jones News
By Alberto Delclaux
Novartis AG (NOVN.EB) said Friday that real-world data showed
that its drug Jakavi is associated with a fall in dangerous blood
clots and risk of death in patients with rare blood cancer.
The pharmaceutical company said a study showed Jakavi-treated
patients with polycythemia vera, who were resistant or intolerant
to hydroxyurea, had a significantly reduced risk compared to
patients who received best available therapy.
The findings were based on a comparison of patients from a
Jakavi clinical trial and data from a Spanish patient registry.
Polycythemia vera is a rare and incurable blood cancer
associated with an overproduction of blood cells, Novartis
said.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
June 15, 2018 03:20 ET (07:20 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024
